Poels, EMP, Kegeles, LS, Kantrowitz, JT, Slifstein, M, Javitt, DC, Lieberman, JA, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry
2014; 19: 20–9.
Coyle, JT, Tsai, G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology
2004; 174: 32–8.
Gilbert-Rahola, J, Villena-Rodriguez, A. Glutamatergic drugs for schizophrenia treatment. Actas espaholas Psiquiatr
2014; 42: 234–41.
Javitt, DC, Zukin, SR, Heresco-Levy, U, Umbricht, D. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull
2012; 38: 958–66.
Théberge, J, Bartha, R, Drost, DJ, Menon, RS, Malla, A, Takhar, J, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry
2002; 159: 1944–6.
Marsman, A, Van Den Heuvel, MP, Klomp, DWJ, Kahn, RS, Luijten, PR, Hulshoff Pol, HE. Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull
2013; 39: 120–9.
Harvey, RJ, Yee, BK. Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov
2013; 12: 866–85.
Williamson, P. Are anticorrelated networks in the brain relevant to schizophrenia?
2007; 33: 994–1003.
Théberge, J, Al-Semaan, Y, Williamson, PC, Menon, RS, Neufeld, RWJ, Rajakumar, N, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry
2003; 160: 2231–3.
Taylor, R, Neufeld, RWJ, Schaefer, B, Densmore, M, Rajakumar, N, Osuch, EA, et al. Functional magnetic resonance spectroscopy of glutamate in schizophrenia and major depressive disorder: anterior cingulate activity during a color-word Stroop task. npj Schizophrenia
2015; 1: 15028 (http://www.nature.com/articles/npjschz201528).
Boksman, K, Théberge, J, Williamson, P, Drost, DJ, Malla, A, Densmore, M, et al. A 4.0-T fMRI study of brain connectivity during word fluency in first-episode schizophrenia. Schizophr Res
2005; 75: 247–63.
Yildiz-Yesiloglu, A, Ankerst, DP. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res Neuroimaging
2006; 147: 1–25.
Chen, LP, Dai, HY, Dai, ZZ, Xu, CT, Wu, RH. Anterior cingulate cortex and cerebellar hemisphere neurometabolite changes in depression treatment: a 1H magnetic resonance spectroscopy study. Psychiatry Clin Neurosci
2014; 68: 357–64.
Coupland, NJ, Ogilvie, CJ, Hegadoren, KM, Seres, P, Hanstock, CC, Allen, PS. Decreased prefrontal myo-inositol in major depressive disorder. Biol Psychiatry
2005; 57: 1526–34.
First, M, Spitzer, R, Gibbon, M, Williams, J. Structured Clinical Interview (SCID) for DSM-IV Axis 1 Disorders.
American Psychiatric Press, 1997.
Andreasen, NC. Scale for the Assessment of Positive Symptoms (SAPS).
The University of Iowa, 1984.
Andreasen NC. Scale for the Assessment of Negative Symptoms (SAPS).
The University of Iowa, 1984.
Montgomery, SA, Asberg, M. Scale designed to be sensitive to change. Br J Psychiatry
1979; 134: 382–9.
Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA. A rating scale for mania: reliability, validity and sensitivity a rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry
2011; 133: 429–35.
Hamilton, M. Rating depressive patients. J Clin Psychiatry
1980; 41(12 pt 2): 21–4.
Aoyama, N, Théberge, J, Drost, DJ, Manchanda, R, Northcott, S, Neufeld, RWJ, et al. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br J Psychiatry
2011; 198: 448–56.
Gilbert, KM, Curtis, AT, Gati, JS, Klassen, LM, Menon, RS. A radiofrequency coil to facilitate B1+ shimming and parallel imaging acceleration in three dimensions at 7 T. NMR Biomed
2011; 24: 815–23.
Curtis, AT, Gilbert, KM, Klassen, LM, Gati, JS, Menon, RS. Slice-by-slice B1+ shimming at 7 T. Magn Reson Med
2012; 68: 1109–16.
Klassen, LM, Menon, RS. Robust automated shimming technique using arbitrary mapping acquisition parameters (RASTAMAP). Magn Reson Med
2004; 51: 881–7.
Tkac, I, Gruetter, R. Methodology of 1 H NMR spectroscopy of the human brain at very high magnetic fields. Appl Magn Reson
2005; 29: 139–57.
Penner, J, Bartha, R. Semi-LASER 1H MR spectroscopy at 7 Tesla in human braIn: metabolite quantification incorporating subject-specific macromolecule removal. Magn Reson Med
2014; 74: 4–12.
Brown, MA. Time-domain combination of MR spectroscopy data acquired using phased-array coils. Magn Reson Med
2004; 52: 1207–13.
Bartha, R, Drost, DJ, Menon, RS, Williamson, PC. Spectroscopic lineshape correction by QUECC: combined QUALITY deconvolution and eddy current correction. Magn Reson Med
2000; 44: 641–5.
Bartha, R, Drost, DJ, Williamson, PC. Factors affecting the quantification of short echo in-vivo 1 H MR spectra: prior knowledge, peak elimination, and filtering. NMR Biomed
1999; 12: 205–16.
Marascuilo, LA, Levin, JR. Multivariate Statistics in the Social Sciences.
Soher, BJ, Young, K, Bernstein, A, Aygula, Z, Maudsley, AA. GAVA: spectral simulation for in vivo MRS applications. J Magn Reson
2007; 185: 291–9.
Krawczyk, H, Gradowska, W. Characterisation of the 1H and 13C NMR spectra of N-acetylaspartylglutamate and its detection in urine from patients with Canavan disease. J Pharm Biomed Anal
2003; 31: 455–63.
Govindaraju, V, Young, K, Maudsley, AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed
2000; 13: 129–53.
Mangia, S, Tkác, I, Gruetter, R, Van de Moortele, P-F, Maraviglia, B, Uğurbil, K. Sustained neuronal activation raises oxidative metabolism to a new steady-state level: evidence from 1H NMR spectroscopy in the human visual cortex. J Cereb Blood Flow Metab
2007; 27: 1055–63.
Mark, LP, Prost, RW, Ulmer, JL, Smith, MM, Daniels, DL, Strottmann, JM, et al. Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging. Am J Neuroradiol
2001; 22: 1813–24.
Kosenko, E, Llansola, M, Montoliu, C, Monfort, P, Rodrigo, R, Hernandez-Viadel, M, et al. Glutamine synthetase activity and glutamine content in braIn: modulation by NMDA receptors and nitric oxide. Neurochem Int
2003; 43: 493–9.
Yamamori, H, Hashimoto, R, Fujita, Y, Numata, S, Yasuda, Y, Fujimoto, M, et al. Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. Neurosci Lett
2014; 582: 93–8.
Hons, J, Vasatova, M, Cermakova, E, Doubek, P, Libiger, J. Different serine and glycine metabolism in patients with schizophrenia receiving clozapine. J Psychiatr Res
2012; 46: 811–8.
Lin, Y, Stephenson, MC, Xin, L, Napolitano, A, Morris, PG. Investigating the metabolic changes due to visual stimulation using functional proton magnetic resonance spectroscopy at 7 T. J Cereb Blood Flow Metab
2012; 32: 1484–95.
Kaufman, MJ, Prescot, AP, Ongur, D, Evins, AE, Barros, TL, Medeiros, CL, et al. Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study. Psychiatry Res – Neuroimaging
2009; 173: 143–9.
Umbricht, D, Alberati, D, Martin-Facklam, M, Borroni, E, Youssef, EA, Ostland, M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry
2014; 71: 637–46.
Strzelecki, D, Podgorski, M, Kaluzynska, O, Gawlik-Kotelnicka, O, Stefanczyk, L, Kotlicka-Antczak, M, et al. Supplementation of antipsychotic treatment with sarcosine – G1yT1 inhibitor – causes changes of glutamatergic 1NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia. Neurosci Lett
2015; 606: 7–12.
Fisher, SK, Novak, JE, Agranoff, BW. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J Neurochem
2002; 82: 736–54.
Barkai, A, Dunner, D, Gross, H, Mayo, P, Fieve, R. Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder. Biol Psychiatry
1978; 13: 65–72.
Kofman, O, Belmaker, RH. Ziskind-Somerfeld Research Award 1993. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression. Biol Psychiatry
1993; 34: 839–52.
Mukai, T, Kishi, T, Matsuda, Y, Iwata, N. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol
2014; 29: 55–63.